



ASX Announcement

12 June 2024

Procurement of Atomo HIV Self-Tests commencing through public health funding

- **Revenue from scale up of the national HIV Self-Test mail-out program estimated to be \$1.3m over 2 years**
- **Vending machine pilot program expanding from a current 6 machines in South Australia up to 70 machines nationally with rollout commencing later this year**
- **Implementation of a separate vending machine pilot program by NSW Health**

SYDNEY Australia, 12 June 2024 – Atomo Diagnostics Limited (ASX:AT1) (Atomo) wishes to provide further updates related to recent government commitments to fund public health expansion of HIV Self-Testing in Australia.

National HIV Self-Test mail-out program

The program run by the National Association of People with HIV Australia (NAPWHA), aims to improve testing rates among at-risk groups through the supply of free HIV self-tests via a mail-out program. This channel has proved extremely successful in reaching key populations, with promotion of the program supported by Grindr to its users being particularly effective in improving program awareness and driving demand.

Based on funding recently committed by the Federal government for expansion of the national program and pricing agreed with NAPWHA for order fulfilment by Atomo, the company is budgeting, not forecasting, revenue from the program over the next two years of approximately \$1.3 million.

Expansion of a HIV testing vending machine pilot to every state and territory:

Federal government funding to expand HIV testing vending machine deployment will see a sizable increase in access to free tests at key locations. The scale up, led by Thorne Harbour Health, will see a South Australian pilot currently operating 6 vending machines increase up to 70 machines nationally under the expansion. The pilot program generated \$25k in revenue for Atomo during FY24, and the company anticipates an increase in sales as new machines coming online later this year are stocked with tests:

Implementation of a Vending machine program by NSW Health:

NSW Health has engaged Atomo to supply HIV self-tests for NSW Health's MyTest pilot project promoting HIV self-testing and provides access to free HIV self-test kits via vending machines for people at risk of HIV in NSW. MyTest is particularly focused on supporting people who



have never been tested for HIV or those who infrequently test for HIV and are not engaged in primary care, as well as those who face barriers to regular sexual health testing due to health insurance or Medicare ineligibility. Currently, five vending machines have been installed with an initial quantity of tests procured from Atomo to support pilot launch. Further installations of vending machines are expected in the coming months.

CEO John Kelly said: “We are encouraged to see the government now investing in HIV Self-Testing as a key tool in the public health response to manage HIV. This follows on from widespread public health adoption of rapid testing during the COVID-19 pandemic and heralds a new era where public health services are increasingly delivered away from hospitals and clinics in decentralised settings, including at-home.”

Mr Kelly added, “Self-testing is now recognised by governments around the world as cost effective to deploy at scale and supporting improved and earlier detection. We anticipate seeing this trend continue with a broader range of infectious disease testing being funded for deployment at home.”

Atomo supplies the only HIV Self-Test included on the Australian Register of Therapeutic Goods (ARTG) and has been instrumental in the implementation of several pilot programs, now being funded directly by the Federal and State Government.

For more information, please contact:

John Kelly
Atomo Diagnostics
john.kelly@atomodiagnostics.com
Phone: +61 401 922 279

This announcement was authorised by the Managing Director & CEO.

About Atomo

Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo’s unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including HIV, COVID-19, viral vs bacterial differentiation, as well as the early detection of pregnancy.

See more at www.atomodiagnostics.com